Exact Sciences Corporation
EXAS
Rang in aandelen
#1151
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Aandeelprijs
$104.91
Laatst gesynchroniseerd: 2026-03-23
Marktkapitalisatie
$20.03B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
71.34%
Land
US
Handel Exact Sciences Corporation (EXAS)
Categorie
Healthcare
EPS voor Exact Sciences Corporation (EXAS)
EPS per December 2025 TTM: $-1.10
Volgens de laatste financiële rapporten en de aandelenkoers van Exact Sciences Corporation is de huidige EPS van het bedrijf (TTM) $-1.10. Eind 2024 had het bedrijf een EPS van $-5.59, een stijging ten opzichte van de EPS van 2023 die $-1.13 bedroeg.
EPS-geschiedenis van Exact Sciences Corporation van 2000 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-1.10 | 0.00% |
| 2025 | $-1.10 | -80.32% |
| 2024 | $-5.59 | 394.69% |
| 2023 | $-1.13 | -68.08% |
| 2022 | $-3.54 | 1.72% |
| 2021 | $-3.48 | -36.15% |
| 2020 | $-5.45 | 236.42% |
| 2019 | $-1.62 | 13.29% |
| 2018 | $-1.43 | 44.44% |
| 2017 | $-0.99 | -39.26% |
| 2016 | $-1.63 | -4.68% |
| 2015 | $-1.71 | 36.80% |
| 2014 | $-1.25 | 81.16% |
| 2013 | $-0.69 | -21.59% |
| 2012 | $-0.88 | 60.00% |
| 2011 | $-0.55 | 96.43% |
| 2010 | $-0.28 | 0.00% |
| 2009 | $-0.28 | -22.22% |
| 2008 | $-0.36 | -18.18% |
| 2007 | $-0.44 | -10.20% |
| 2006 | $-0.49 | -10.91% |
| 2005 | $-0.55 | -24.66% |
| 2004 | $-0.73 | -51.33% |
| 2003 | $-1.50 | -7.41% |
| 2002 | $-1.62 | 14.08% |
| 2001 | $-1.42 | -82.53% |
| 2000 | $-8.13 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $18.62 | -1,792.73% |
US
|
|
| $5.65 | -613.64% |
US
|
|
| $-1.36 | 23.64% |
US
|
|
| - | - |
CN
|
|
| $5.09 | -562.73% |
US
|
